190 related articles for article (PubMed ID: 19358416)
21. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
23. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
Gridelli C; Rossi A
Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
[TBL] [Abstract][Full Text] [Related]
24. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.
Leon L; Vázquez S; Gracia JM; Casal J; Lazaro M; Firvida JL; Amenedo M; Santome L; Macia S
Expert Opin Pharmacother; 2012 Jul; 13(10):1389-96. PubMed ID: 22630129
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab for non-small-cell lung cancer.
Sculier JP; Meert AP; Paesmans M
N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
[No Abstract] [Full Text] [Related]
27. Selection of chemotherapy for patients with advanced non-small cell lung cancer.
Pennell NA
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS46-50. PubMed ID: 22614966
[TBL] [Abstract][Full Text] [Related]
28. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
29. Exploring the future of non-small cell lung cancer treatment.
Ramalingam S
Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
[No Abstract] [Full Text] [Related]
30. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
Bauman JE; Eaton KD; Martins RG
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4632-6. PubMed ID: 17671155
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab in non-small-cell lung cancer: a review.
Planchard D
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
Socinski MA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
[TBL] [Abstract][Full Text] [Related]
33. Off-label uses of bevacizumab: breast and lung cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
[No Abstract] [Full Text] [Related]
34. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
36. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
Dowlati A
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab: current updates in treatment.
Van Meter ME; Kim ES
Curr Opin Oncol; 2010 Nov; 22(6):586-91. PubMed ID: 20811277
[TBL] [Abstract][Full Text] [Related]
38. Development of new first-line therapeutic options for non-small-cell lung cancer.
Crinò L; Foglietta J; Hamzaj A
Lung Cancer; 2006 Dec; 54 Suppl 2():S19-24. PubMed ID: 17056151
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
Dasanu CA
J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab in lung cancer: hurdles in clinical development.
Pirker R
Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
